
Jupiter’s investment objective
is to achieve superior absolute returns, while doing so on an attractive risk-adjusted basis.
View additional investment strategies
Principal Investment Areas
Jupiter’s private equity activities are focused on acquiring controlling interests in excellent middle market companies with strong management at fair valuations.
We are actively seeking new investments and encourage executives, investment banking firms, business brokers, attorneys, accountants and business owners/managers to contact us with investment opportunities, ideas or questions. We have no committees and respond rapidly as to whether we’re interested in a particular opportunity, typically within a few days.
Acquisition Criteria
-
Management and Leveraged buyouts (MBO & LBO)
Recapitalizations
Corporate divestitures
Growth and expansion investments
-
Established and defensible market position (unique or proprietary products, services or customers; or product, cost or other advantages)
Quality management in-place (we are prepared to augment, but not replace)
Established and profitable operating history with healthy operating margins and proven free cash flow generation
High returns on invested capital
Attractive growth prospects, both internal and external
Stable or growing markets with limited cyclicality
Limited risk of technological obsolescence
Simple, understandable businesses
Fair valuation
Headquartered in the U.S., with a preference to Western U.S.
-
Total enterprise values ranging from $25 to $500 million
Controlling equity investments of $5 to $100 million
EBITDA of $5 million or greater
Company revenues of $25 million or greater
-
We are generalist investors, and industry segment is our least important criterion.
Industries of interest and experience include:
Consumer Products and Services
Retail & Restaurants
Franchisors/Franchisees
Business Services
Basic Manufacturing
Value-Added Distribution
Healthcare Services
Energy, Transportation & Distribution
Investment areas typically avoided include:
High technology
Biotechnology
Startups
PRIVATE EQUITY